Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-08
DOI
10.1007/s40265-020-01431-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis
- (2020) Alessandra Musella et al. Cells
- Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
- (2019) Jerold Chun et al. Annual Review of Pharmacology and Toxicology
- Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
- (2019) Sara Grassi et al. Frontiers in Pharmacology
- Lymphocyte counts and infection rates
- (2019) Edward J. Fox et al. Neurology-Neuroimmunology & Neuroinflammation
- Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
- (2019) Brandon Brown et al. BMC Neurology
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- S1P/S1P Receptor Signaling in Neuromuscolar Disorders
- (2019) Elisabetta Meacci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling
- (2018) Yin-Feng Dong et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis
- (2018) Paul A. Smith et al. JOURNAL OF NEUROIMMUNOLOGY
- Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma
- (2018) Salvatore Cuzzocrea et al. JOURNAL OF NEUROTRAUMA
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
- (2018) Andrea Huwiler et al. PHARMACOLOGY & THERAPEUTICS
- Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells migration in multiple sclerosis patients
- (2018) Pasquale Annunziata et al. Scientific Reports
- Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study
- (2018) Irene Moreno-Torres et al. Frontiers in Immunology
- Ozanimod for the treatment of relapsing remitting multiple sclerosis
- (2018) Ludwig Rasche et al. EXPERT OPINION ON PHARMACOTHERAPY
- ‘Crystal’ Clear? Lysophospholipid Receptor Structure Insights and Controversies
- (2018) Victoria A. Blaho et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A Novel Perspective on the ApoM-S1P Axis, Highlighting the Metabolism of ApoM and Its Role in Liver Fibrosis and Neuroinflammation
- (2017) Stefan Hajny et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
- (2017) Jonathan Q. Tran et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes
- (2017) Stephanie S. Dusaban et al. Journal of Neuroinflammation
- Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair
- (2017) Yuan Zhang et al. MOLECULAR THERAPY
- Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells
- (2017) Nigel Pyne et al. MOLECULES
- Oral Presentations
- (2017) Multiple Sclerosis Journal
- Late Breaking News Abstracts
- (2017) Multiple Sclerosis Journal
- The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
- (2017) Abdelkrim Mannioui et al. Multiple Sclerosis Journal
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases
- (2017) Sinead O'Sullivan et al. NEUROPHARMACOLOGY
- Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation
- (2017) Veit Rothhammer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
- (2017) Alberto Gajofatto Drug Design Development and Therapy
- Oral Presentations
- (2017) Multiple Sclerosis Journal
- Late Breaking News Abstracts
- (2017) Multiple Sclerosis Journal
- The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
- (2017) Abdelkrim Mannioui et al. Multiple Sclerosis Journal
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes
- (2017) Pernille M. Christensen et al. Scientific Reports
- Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
- (2016) Kunio Sugahara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
- (2016) F L Scott et al. BRITISH JOURNAL OF PHARMACOLOGY
- Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
- (2016) Antonietta Gentile et al. Journal of Neuroinflammation
- The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
- (2016) Catherine O’Sullivan et al. Journal of Neuroinflammation
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
- (2016) Ludwig Kappos et al. LANCET NEUROLOGY
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism
- (2016) Dominik Vogt et al. MEDICINAL RESEARCH REVIEWS
- Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans
- (2016) Stipo Jurcevic et al. Drug Design Development and Therapy
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
- (2016) Ludwig Kappos et al. JAMA Neurology
- Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1
- (2015) Jill E. Chrencik et al. CELL
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
- The Role of Circulating Tight Junction Proteins in Evaluating Blood Brain Barrier Disruption following Intracranial Hemorrhage
- (2015) Xiaoyang Jiao et al. DISEASE MARKERS
- Lysophospholipid receptors in drug discovery
- (2015) Yasuyuki Kihara et al. EXPERIMENTAL CELL RESEARCH
- Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
- (2015) Sonja Krösser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
- (2015) Georgia Mandolesi et al. Nature Reviews Neurology
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720)
- (2015) A. Yazdi et al. NEUROSCIENCE
- Sphingosine 1-phosphate signaling at the blood–brain barrier
- (2015) Briana Prager et al. TRENDS IN MOLECULAR MEDICINE
- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Lysophospholipid receptor nomenclature review: IUPHAR Review 8
- (2014) Yasuyuki Kihara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Brain atrophy in natalizumab-treated patients: A 3-year follow-up
- (2014) J Sastre-Garriga et al. Multiple Sclerosis Journal
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
- (2014) Edward Fox et al. Multiple Sclerosis and Related Disorders
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Second generation S1P pathway modulators: Research strategies and clinical developments
- (2013) Marc Bigaud et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Modulators of the Sphingosine 1-phosphate receptor 1
- (2013) Mariangela Urbano et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study
- (2013) Patrick Brossard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lysophosphatidic acid (LPA) and its receptor, LPA1, influence embryonic schwann cell migration, myelination, and cell-to-axon segregation
- (2013) Brigitte Anliker et al. GLIA
- Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
- (2013) Celina Wu et al. Journal of Neuroinflammation
- Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
- (2013) Aran Groves et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
- (2013) Gregory T. Kunkel et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
- (2013) Shifeng Pan et al. ACS Medicinal Chemistry Letters
- Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects
- (2012) Eric Legangneux et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3receptor ligands using the DiscoveRx PathHunter™ and Ca2+release functional assays
- (2012) DM Riddy et al. BRITISH JOURNAL OF PHARMACOLOGY
- Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients
- (2012) R. Kazmierski et al. NEUROLOGY
- Crystal Structure of a Lipid G Protein-Coupled Receptor
- (2012) M. A. Hanson et al. SCIENCE
- Insights into the pharmacological relevance of lysophospholipid receptors
- (2011) Tetsuji Mutoh et al. BRITISH JOURNAL OF PHARMACOLOGY
- Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors
- (2011) Victoria A. Blaho et al. CHEMICAL REVIEWS
- Sphingosine-1-phospate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model
- (2011) Tobias Schulze et al. FASEB JOURNAL
- Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model
- (2011) Hye Jung Kim et al. FASEB JOURNAL
- S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures
- (2011) Graham K. Sheridan et al. GLIA
- Fingolimod modulates microglial activation to augment markers of remyelination
- (2011) Samuel J Jackson et al. Journal of Neuroinflammation
- The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
- (2011) L. Piali et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators
- (2011) B. Soliven et al. NEUROLOGY
- Sphingosine Kinase 1 and Sphingosine 1-Phosphate Receptor 3 Are Functionally Upregulated on Astrocytes under Pro-Inflammatory Conditions
- (2011) Iris Fischer et al. PLoS One
- Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
- (2010) Veronique E. Miron et al. AMERICAN JOURNAL OF PATHOLOGY
- LPA Receptors: Subtypes and Biological Actions
- (2010) Ji Woong Choi et al. Annual Review of Pharmacology and Toxicology
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- The lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) receptor gene families: cloning and comparative expression analysis in Xenopus laevis
- (2010) Karine Masse et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Autotaxin and Lysophosphatidic Acid1 receptor-Mediated Demyelination of Dorsal Root Fibers by Sciatic Nerve Injury and Intrathecal Lysophosphatidylcholine
- (2010) Jun Nagai et al. Molecular Pain
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
- (2010) J. W. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P3)
- (2009) M Jongsma et al. BRITISH JOURNAL OF PHARMACOLOGY
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
- (2009) Volker Brinkmann BRITISH JOURNAL OF PHARMACOLOGY
- T-bet–dependent S1P5expression in NK cells promotes egress from lymph nodes and bone marrow
- (2009) Craig N. Jenne et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biological roles of lysophospholipid receptors revealed by genetic null mice: An update
- (2008) J CHOI BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
- "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
- (2008) K. Takabe et al. PHARMACOLOGICAL REVIEWS
- FTY720 modulates human oligodendrocyte progenitor process extension and survival
- (2007) Veronique E. Miron et al. ANNALS OF NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More